Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer

Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sata, Masafumi, Sasaki, Shinichi, Oikado, Katsunori, Saito, Yoshinobu, Tominaga, Junya, Sakai, Fumikazu, Kato, Terufumi, Iwasawa, Tae, Kenmotsu, Hirotsugu, Kusumoto, Masahiko, Baba, Tomohisa, Endo, Masahiro, Fujiwara, Yutaka, Sugiura, Hiroaki, Yanagawa, Noriyo, Ito, Yoshihiko, Sakamoto, Takahiko, Ohe, Yuichiro, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019226/
https://www.ncbi.nlm.nih.gov/pubmed/33125784
http://dx.doi.org/10.1111/cas.14715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019226/
https://www.ncbi.nlm.nih.gov/pubmed/33125784
http://dx.doi.org/10.1111/cas.14715

Ejemplares similares